Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.31M P/E - EPS this Y 42.70% Ern Qtrly Grth -
Income -14.42M Forward P/E -0.85 EPS next Y 22.40% 50D Avg Chg -36.00%
Sales 145.8k PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -60.00%
Recommedations 2.00 Quick Ratio 10.42 Shares Outstanding 6.77M 52W Low Chg 22.00%
Insider Own 18.80% ROA -65.50% Shares Float 5.49M Beta 61.53
Inst Own 15.23% ROE -105.30% Shares Shorted/Prior 169.57K/40.50K Price 2.84
Gross Margin 100.00% Profit Margin - Avg. Volume 75,067 Target Price 10.50
Oper. Margin -16,687.47% Earnings Date Aug 9 Volume 14,187 Change 0.71%
About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.

BioRestorative Therapies, Inc. News
05/15/24 BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
05/14/24 BioRestorative Therapies Provides First Quarter 2024 Business Update
05/08/24 BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
04/30/24 BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04/30/24 BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
04/16/24 BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
04/14/24 10 Micro-Cap Healthcare Stocks Insiders Are Buying
04/08/24 BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
04/03/24 BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
04/03/24 BioRestorative Therapies Full Year 2023 Earnings: Beats Expectations
04/01/24 BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
03/11/24 BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
02/15/24 Favourable Signals For BioRestorative Therapies: Numerous Insiders Acquired Stock
02/14/24 BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
02/06/24 BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
02/05/24 BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
02/01/24 BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
12/12/23 BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
12/03/23 11 Most Volatile Stocks Under $5 For Day Trading
10/09/23 BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
BRTX Chatroom

User Image boymonkey01 Posted - 2 days ago

$BRTX What happened to Q1 earnings? May 14?

User Image Stock_Titan Posted - 4 days ago

$BRTX BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-nasdaq-brtx-announces-commercial-agreement-b7dkxq90w9h8.html

User Image TheTradeXchange Posted - 4 days ago

$BRTX BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

User Image Chief_Beachbum Posted - 4 days ago

$BRTX …I haven’t looked at this in a year. What a dog, with fleas.

User Image Omega_Proxy Posted - 4 days ago

$BRTX I think this is going to take off as soon as they actually start showing that they're making money 😂

User Image Stock_Titan Posted - 4 days ago

$BRTX BioRestorative Therapies Provides First Quarter 2024 Business Update https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-provides-first-quarter-2024-business-t7lav5kg3l98.html

User Image Benzinga Posted - 4 days ago

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market $BRTX https://www.benzinga.com/partner/biotech/24/05/38815704/biorestorative-therapies-nasdaq-brtx-announces-commercial-agreement-with-cartessa-further-expandi

User Image Omega_Proxy Posted - 4 days ago

$BRTX 👀

User Image Bdin42 Posted - 6 days ago

$BRTX I think this on is going to take off AH tomorrow with earnings and the call! Just picked up more

User Image AProFoundation Posted - 6 days ago

$BRTX still a better risk than Mullen lol

User Image Rahmmy Posted - 1 week ago

$BRTX They’re going to solve degenerative disc disease and cure obesity but only a $9 million market cap? Don’t you think a pharma or biotech co would buy then for $50mln (5x current value) if their products were worth anything?

User Image stockregion Posted - 1 week ago

The global obesity treatment market is vast and growing, driven by increasing obesity rates worldwide and a high demand for effective treatments. BioRestorative Therapies, Inc. (NASDAQ:BRTX), a company in the industry of stem cell-based therapies, is poised to revolutionize the treatment landscape for obesity with its latest venture into exosome-based biologics. This approach, leveraging the company's proprietary ThermoStem® technology, marks a significant advancement in addressing a global health crisis that continues to escalate. $BRTX https://stockregion.app/p/cell-therapy-company-expands-its

User Image Omega_Proxy Posted - 1 week ago

$BRTX I smell fear.

User Image Omega_Proxy Posted - 1 week ago

$BRTX Good news, but someone is trying to shake out swingers and or, bit enough positive buying action, so would be swingers capitulated. Who knows. Bottom line. It's a POS. Makes me bullish 😂

User Image Bdin42 Posted - 1 week ago

$BRTX how is it lately that every stock I have that puts out positive news goes down that day?????

User Image OdaSkills_Invests Posted - 1 week ago

$BRTX Exciting news from BioRestorative Therapies! Their latest ThermoStem technology could transform obesity treatment, offering a potential alternative to traditional weight loss medications. With proven efficacy in preclinical trials, #BRTX is paving the way for future pharma collaborations.

User Image DonCorleone77 Posted - 1 week ago

$BRTX BioRestorative develops new therapeutic candidate using ThermoStem platform BioRestorative Therapies announced its development of a novel exosome-based biologic program targeting obesity. BioRestorative currently anticipates initiating the formal U.S. FDA process for this ThermoStem-based therapeutic candidate by filing a Drug Master File in the third quarter of 2024. The company aims to initiate first-in-human clinical studies before the end of the year. "We believe that our proprietary ThermoStem technology platform has immense potential to develop both best-in-class and first-in-class therapies to treat obesity, such as this exosome-based biologic candidate," said Lance Alstodt, BioRestorative's CEO. "While tremendous progress has been made in the fight against obesity, there is no question that significant unmet need remains. As an adjuvant to approved and marketed weight loss drugs, we believe that our new therapeutic candidate may allow for lower dosing, as well as prevent or minimize potential of muscle mass loss and negative cardiovascular effects."

User Image ChubbyPanda Posted - 1 week ago

$BRTX so this is actually bad news?

User Image premarketmaker Posted - 1 week ago

$BRTX

User Image Stock_Titan Posted - 1 week ago

$BRTX BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity https://www.stocktitan.net/news/BRTX/bio-restorative-therapies-enhances-preclinical-metabolic-program-8ktud242hhti.html

User Image Omega_Proxy Posted - 1 week ago

$BRTX Hold for swing. I'll signal when to swing.

User Image Omega_Proxy Posted - 1 week ago

$BRTX not dropping back down so that is good

User Image BioTuesdays Posted - 1 week ago

BioRestorative Therapies announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics $BRTX https://biotuesdays.com/2024/04/30/biorestorative-therapies-and-cartessa-aesthetics-collaborate-to-build-a-vertically-integrated-best-in-class-biocosmeceutical-platform/

User Image OdaSkills_Invests Posted - 1 week ago

$BRTX Let's keep it going!!

User Image intratio Posted - 2 weeks ago

$BRTX https://www.intratio.com/stock-forecast/BRTX The machine learning model deduces that this stock s price action will climb in the short run and has no clear long-term directional perspective

User Image OdaSkills_Invests Posted - 2 weeks ago

$BRTX Let's keep it going !!!

User Image RideTheWave32 Posted - 2 weeks ago

$BRTX 1.50 on deck then to 1.60, then 1.85+

User Image gobuckeyes21 Posted - 2 weeks ago

$BRTX more people trapped in the mini pump … Lance is a conman. If you get 10-15%, get out before this heads below a dollar because it’s coming

User Image Belle0314 Posted - 2 weeks ago

$BRTX I've been in and out since the OTC days. The company has made significant strides. But when you know you know... still facing a lot of debt. Heavy dilution...Swing Responsibly! 1.25 is a good entry point! Anything above 1.25 do not hold unless you intend to go long.

User Image RideTheWave32 Posted - 2 weeks ago

$BRTX the climb back to 1.45, 1.50, and then back to 1.85-2+ territory. today, tomorrow or the next day Paytience pays 👍🏻👍🏻👍🏻👍🏻

Analyst Ratings
Roth MKM Buy Aug 14, 23
Roth Capital Buy Dec 7, 22
Maxim Group Buy Sep 28, 22
Roth Capital Buy Dec 1, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Broadrick Dale 10% Owner 10% Owner Nov 27 Sell 1.89 278 525 327,295 12/01/23
Broadrick Dale 10% Owner 10% Owner Sep 14 Buy 1.6 20,000 32,000 327,573 09/18/23
Broadrick Dale 10% Owner 10% Owner Jul 27 Buy 2.8 1,000 2,800 306,073 07/28/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 25 Buy 2.44 4,200 10,248 184,418 07/25/23
Silva Francisco VP of Research and D.. VP of Research and Development Mar 31 Buy 3.56 747 2,659 159,690 04/04/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 27 Buy 3.01 200 602 186,921 01/30/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 18 Buy 3.1 400 1,240 186,521 01/20/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 09 Buy 3.08 100 308 186,121 01/10/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 23 Buy 3.01 300 903 186,021 12/28/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 07 Buy 2.9861 1,800 5,375 185,721 12/07/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Nov 18 Buy 2.8765 1,000 2,876 183,921 11/21/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Sep 22 Buy 2.92 200 584 182,921 09/23/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Buy 3.29 5,723 18,829 12,136 09/09/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Sell 3.39 3,958 13,418 158,156 09/09/22
Broadrick Dale 10% Owner 10% Owner Jul 06 Buy 3.12 1,200 3,744 298,573 07/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 12 Buy 2.95 700 2,065 182,721 07/13/22
Broadrick Dale 10% Owner 10% Owner Jun 30 Buy 3.0789 1,900 5,850 297,373 07/05/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 30 Buy 3.0981 1,100 3,408 182,021 07/01/22
Broadrick Dale 10% Owner 10% Owner Jun 15 Buy 3.76 3,200 12,032 294,773 06/17/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 15 Buy 3.61 194 700 7,994 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 15 Buy 3.6822 700 2,578 180,321 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 14 Buy 3.9119 500 1,956 179,621 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 13 Buy 3.95 200 790 179,121 06/14/22
Broadrick Dale 10% Owner 10% Owner Jun 09 Buy 4.25 1,600 6,800 290,273 06/13/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 08 Buy 4.28 100 428 178,921 06/09/22
Broadrick Dale 10% Owner 10% Owner Jun 03 Buy 4.92 4,200 20,664 282,673 06/07/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 07 Buy 4.56 200 912 7,800 06/07/22
Broadrick Dale 10% Owner 10% Owner Jun 02 Buy 4.6878 1,000 4,688 278,473 06/06/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 01 Buy 4.6 200 920 178,821 06/03/22
Broadrick Dale 10% Owner 10% Owner May 26 Buy 3.51 4,950 17,374 259,303 05/31/22
Broadrick Dale 10% Owner 10% Owner May 26 Sell 3.44 2,000 6,880 257,303 05/31/22
ALSTODT LANCE President, CEO, COB President, CEO, COB May 02 Buy 3.95 400 1,580 175,921 05/02/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Apr 08 Buy 5.71 7,600 43,396 7,600 04/11/22
Broadrick Dale 10% Owner 10% Owner Apr 06 Buy 5.66 2,500 14,150 254,353 04/08/22
Broadrick Dale 10% Owner 10% Owner Mar 29 Buy 4.89 15,700 76,773 316,972 04/01/22
Broadrick Dale 10% Owner 10% Owner Mar 01 Buy 4.87 155,950 759,476 205,853 03/29/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 24 Buy 3.4 1,470 4,998 163,083 01/24/22